Share

Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

Dr Denis Lacombe, CEO of EORTC, has been appointed as the stakeholder co-chair of the ACT EU advisory group for a two-year mandate. This role offers new opportunities to collaborate more closely with regulatory bodies and other stakeholders, addressing daily challenges and developing new opportunities for conducting clinical research in Europe.

Additionally, Stephanie Kromar, Head of the Regulatory Department, and Stephane Lejeune, Head of the International Affairs and Policies Department, will represent EORTC on the ACT EU Advisory Group.

ACT EU is a unique initiative aimed at optimising the conduct of clinical research in Europe by addressing challenges arising from the rapidly evolving regulatory ecosystem and developing a specific scheme for academic clinical research.

ACT EU’s mission is to transform the initiation, design, and execution of clinical trials, promoting the development of high-quality, safe, and effective medicines. It also seeks to better integrate clinical research within the European health system. For more detailed information, visit Accelerating Clinical Trials in the EU (ACT EU) | European Medicines Agency (europa.eu).

Back to news list

Related News

  • SISAQOL-IMI Consortium Launches Final Recommendations

  • World Cancer Day 2025: EORTC’s commitment to older patients

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024